Innate Pharma SA

IPHA Nasdaq SEC CIK 1598599
Follow Innate Pharma Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €9M −55.2% vs prior year
Net income −€49.2M +0.6% vs prior year
EPS, diluted −€0.55 +9.8% vs prior year
Operating cash flow −€52.8M −665% vs prior year
Revenue by fiscal year
€69.8M
€24.7M
€57.7M
€61.6M
€20.1M
€9M
FY20 FY21 FY22 FY23 FY24 FY25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−€100M−€50M€0€50M€100MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25€9M−€49.2M
FY24€20.1M−€49.5M
FY23€61.6M−€7.6M
FY22€57.7M−€58.1M
FY21€24.7M−€52.8M
FY20€69.8M−€64M
FY19€85.4M−€20.8M
FY18€94M€3M
FY17€44M−€48.4M
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−599.8%−546.1%
FY24−256.3%−245.9%
FY23−20.6%−12.3%
FY22−99.6%−100.7%
FY21−193.6%−213.8%
FY201.5%−91.7%
FY191.8%−24.3%
FY185.5%3.2%
FY17−90.8%−109.9%
FY16--
Free cash flowOperating cash flow minus capital expenditure
−€75M−€50M−€25M€0€25M€50MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−€52.9M
FY24−€7.3M
FY23−€32.9M
FY22−€19.7M
FY21−€59.4M
FY20−€52.7M
FY19€33.7M
FY18−€33.4M
FY17−€51M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Innate Pharma
  • Healthcare median
−600%−400%−200%0%200%FY17FY19FY21FY23FY25
Show the numbers
YearInnate PharmaHealthcare median
FY25−546.1%−30.6%
FY24−245.9%−47%
FY23−12.3%−58%
FY22−100.7%−80.4%
FY21−213.8%−71.8%
FY20−91.7%−62.2%
FY19−24.3%−46.2%
FY183.2%−49.6%
FY17−109.9%−45.9%
FY16-−36%